Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective
✍ Scribed by François P. Sarasin; Pietro E. Majno; Josep M. Llovet; Jordi Bruix; Gilles Mentha; Antoine Hadengue
- Book ID
- 118686796
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 211 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Liver transplantation (LT) is the treatment of choice for early hepatocellular carcinoma (HCC) in patients with end-stage liver disease but is limited by the availability of donor organs. Living donor liver transplantation (LDLT) represents an alternative therapeutic option for patients with disease
In regions with a limited deceased donor pool, living donor adult liver transplantation (LDALT) has become an important treatment modality for patients with hepatocellular carcinoma (HCC) and cirrhosis. Studies have shown higher recurrence rates of HCC after LDALT in comparison with deceased donor l